The review article titled"Current insights and future directions in Peyronie's disease management: A narrative review", was ...
Endo, Inc. (OTCQX: NDOI) announced today the launch of a first-of-its-kind initiative for a pharmaceutical company: the ...
Endo, Inc. (OTCQX: NDOI) announced today that data related to the use of XIAFLEX® (collagenase clostridium histolyticum, or CCH) for the treatment ...
Experts have met to discuss the risks and knowledge gaps around Clostridium botulinum and Clostridium perfringens. At a Food and Agriculture Organization (FAO) meeting in Rome in February ...
Endo’s portfolio includes Xiaflex (collagenase clostridium histolyticum) for Dupuytren’s contracture and Peyronie’s disease, as well as a range of generics and sterile injectables. As part of the ...
Endo, Inc. (OTCQX: NDOI) announced today that a post hoc data analysis of a Phase 3 clinical trial of XIAFLEX® (collagenase clostridium histolyticum, or CCH) in patients with Peyronie's disease (PD) ...
March 12, 2025 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) announced today that a post hoc data analysis of a Phase 3 clinical trial of XIAFLEX ® (collagenase clostridium histolyticum, or CCH ...
For some people, the condition may only cause lumps in the palm and never worsen, while others may develop severely bent fingers that cannot be fully straightened. If the lumps or contractures ...